Mi Qiuwen, Cui Baoliang, Chávez Daniel, Chai Heebyung, Zhu Haiyuan, Cordell Geoffrey A, Hedayat Sam, Kinghorn A Douglas, Pezzuto John M
Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 60612 USA.
Anticancer Res. 2002 May-Jun;22(3):1385-97.
P-Glycoprotein (Pgp) associated multidrug-resistance (MDR) is a significant factor that can lead to the failure of cancer chemotherapy. Several new tropane alkaloid aromatic esters obtained from extracts of Erythroxylum pervillei Baillon (Erythroxylaceae) (1-8) and Erythroxylum rotundifolium Lunan (Erythroxylaceae) (9-12) by means of bioassay-directed fractionation were found to restore vinblastine sensitivity with cultured multidrug-resistant KB-VI cells. With this model, growth was not inhibited by addition of vinblastine (1 microg/ml) to the culture medium, but in combination with tropane alkaloids, inhibition was observed with IC50 values categorized as: low (ranging from 0.17-0.62 microM) for 1 [3alpha-phenylacetoxy-6beta-(3,4,5-trimethaxycinnamoyloxy)-tropane], 3 [3alpha-(3,4,5-trimethoxybenzoyloxy)-6beta-(3,4,5-trimethoxycinnamoyloxy)tropane], 4 [3alpha-(3,4,5-trimethoxybenzoyloxy)-6beta-(3,4,5-trimethoxycinnamoyloxy)-7beta-hydroxytropane], 5 [3alpha,6beta-di-(3,4,5-trimethoxycinnamoyloxy)tropane], 6 [3alpha,6beta-di-(3,4,5-trimethoxycinnamoyloxy)-7beta-hydroxytropane] and 9 [6beta-benzoyloxy-3alpha-(3,4,5-trimethoxycinnamoyloxy)tropane]; medium (2.0-3.7 microM) for 2 [3alpha-(3-hydroxyphenylacetoxy)-6beta-(3,4,5-trimethoxycinnamoyloxy)tropane] and 10 [7beta-acetoxy-6beta-benzoyloxy-3alpha-(3,4,5-trimethoxycinnamoyloxy)tropane]; or high (9.8 microM) for 11 [6beta-benzoyloxy-3alpha-(3,4,5-trimethoxycinnamoyloxy)tropane-7beta-ol]. Compounds 7 (tropane-3alpha,6beta,7beta-triol 3-phenylacetate), 8 (1alphaH, 5alphaH-tropan-3alpha-yl 3,4,5-trimethoxybenzoate) and 12 (6beta-(3,4,5-trimethoxybenzoyloxy)-3alpha-(3,4,5-trimethoxycinnamoyloxy)tropane-7beta-ol) were not active. Among the active compounds, 1 and 3-6 were further tested with drug-resistant CEM/VLB100 cells. In the presence of modulator, sensitivity to vinblastine increased by 50-5,000-fold. Treatment of KB-V1 cells with 1 or 3-6 enhanced the intracellular accumulation of fluorescence dye (rhodamine 123). Visualization by confocal microscopy confirmed the intracellular accumulation of rhodamine 123 in drug-resistant KB-V1 cells was significantly less than drug-sensitive KB-3 cells, while treatment of KB-V1 cells with 10 microM 4 significantly increased intracellular accumulation. The molecular characteristics of the isolates were then determined and compared with their potential to reverse drug resistance. ClogP and molar refractivity were weakly correlated with their potential to reverse MDR
P-糖蛋白(Pgp)相关的多药耐药性(MDR)是导致癌症化疗失败的一个重要因素。通过生物活性导向分离法从秘鲁古柯(古柯科)提取物(1-8)和圆叶古柯(古柯科)提取物(9-12)中获得的几种新的托烷生物碱芳香酯,被发现可恢复长春碱对培养的多药耐药KB-VI细胞的敏感性。在该模型中,向培养基中添加长春碱(1微克/毫升)不会抑制细胞生长,但与托烷生物碱联合使用时,可观察到抑制作用,其IC50值分类如下:对1[3α-苯乙酰氧基-6β-(3,4,5-三甲氧基肉桂酰氧基)托烷]、3[3α-(3,4,5-三甲氧基苯甲酰氧基)-6β-(3,4,5-三甲氧基肉桂酰氧基)托烷]、4[3α-(3,4,5-三甲氧基苯甲酰氧基)-6β-(3,4,5-三甲氧基肉桂酰氧基)-7β-羟基托烷]、5[3α,6β-二(3,4,5-三甲氧基肉桂酰氧基)托烷]、6[3α,6β-二(3,4,5-三甲氧基肉桂酰氧基)-7β-羟基托烷]和9[6β-苯甲酰氧基-3α-(3,4,5-三甲氧基肉桂酰氧基)托烷]为低(0.17-0.62微摩尔);对2[3α-(3-羟基苯乙酰氧基)-6β-(3,4,5-三甲氧基肉桂酰氧基)托烷]和10[7β-乙酰氧基-6β-苯甲酰氧基-3α-(3,4,5-三甲氧基肉桂酰氧基)托烷]为中等(2.0-3.7微摩尔);对11[6β-苯甲酰氧基-3α-(3,4,5-三甲氧基肉桂酰氧基)托烷-7β-醇]为高(9.8微摩尔)。化合物7(托烷-3α,6β,7β-三醇3-苯乙酸酯)、8(1αH,5αH-托烷-3α-基3,4,5-三甲氧基苯甲酸酯)和12(6β-(3,4,5-三甲氧基苯甲酰氧基)-3α-(3,4,5-三甲氧基肉桂酰氧基)托烷-7β-醇)无活性。在活性化合物中,1和3-6进一步用耐药CEM/VLB100细胞进行测试。在存在调节剂的情况下,对长春碱的敏感性提高了50-5000倍。用1或3-6处理KB-V1细胞可增强荧光染料(罗丹明123)的细胞内积累。共聚焦显微镜观察证实,耐药KB-V1细胞中罗丹明123的细胞内积累明显少于药物敏感的KB-3细胞,而用10微摩尔4处理KB-V1细胞可显著增加细胞内积累。然后确定分离物的分子特征,并与其逆转耐药性的潜力进行比较。ClogP和摩尔折射度与其逆转MDR的潜力呈弱相关